ALLERGY THERAPEUTICS PLC

Capital/Financing Update • Apr 17, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9808E

Allergy Therapeutics PLC

17 April 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Extension of Convertible Loan Note with CFR International SpA

Allergy Therapeutics plc, the fully integrated specialty pharmaceutical company, announces that CFR International SpA and the Company have agreed to extend the term of the £4.04 million convertible loan made available to the Company on 30 March 2012. The date of maturity of the convertible loan has been extended from 20 April 2014 to 30 September 2014. All other terms for the Convertible Loan remain unchanged.

Ends-

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel Clare Terlouw
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway Victoria Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of almost £40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFILSTIRLIS